Hesperos and Bayer Consumer Health develop frst human-on-a-chip model of stress-induced cognitive dysfunction

New study presents a human-relevant stress model for assessing potential therapeutics

FDA approves Zydus’ Deflazacort oral suspension, 22.75 mg/mL

Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older

Lupin receives FDA approval Rivaroxaban for oral suspension

The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India

Lupin acquires VISUfarma to strengthen specialty ophthalmology portfolio

Briefs: Relonchem, Patel Chem Specialities and J & H Pharma Consultants

Relonchem receives marketing authorization for Moxonidine tablets

Shilpa Medicare receives initial authorization for Rivaroxaban Orodispersible films from EMA

FDA completes inspection of Indoco’s API manufacturing facility at Patalganga with zero observations

The inspection concluded with zero form 483 observations

ProBioGen to spearhead GMP manufacturing at Berlin’s gene & cell therapy hub

ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit

Zen Multispeciality Hospital bags CII WR Health Innovation award 2025

The hospital was recognised as a Winner (Medium) in the category of Best Academic Institution (Government/Private)

Mycenax and Spera forge alliance to streamline ADC drug substance